Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma

References

• Went M, Sud A, Forsti A, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9(1):3707.
   PubMedGoogle Scholar
• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–477.
   PubMed Web of Science ®Google Scholar
• Chen L, Li Z, Li S, et al. Prognostic value and efficacy evaluation of novel drugs for multiple myeloma patients with 1q21 amplification (Amp1q21) only: a systematic review of randomized controlled trials. J Cancer. 2020;11(9):2639–2644.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Bataille R, Annweiler C, Beauchet O. Multiple myeloma international staging system: “staging” or simply “aging” system?. Clin Lymphoma Myeloma Leuk. 2013;13(6):635–637.
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol 2022: JCO2102614.
   PubMed Web of Science ®Google Scholar
• Fang EF, Xie C, Schenkel JA, et al. A research agenda for ageing in China in the 21st centuryFocusing on basic and translational research, long-term care, policy and social networks. 2nd Ageing Res Rev. 2020;64:101174
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–348.
   PubMed Web of Science ®Google Scholar
• Hu Y, Lin J, Fang H, et al. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018;32(10):2250–2262.
   PubMed Web of Science ®Google Scholar
• Taiana E, Favasuli V, Ronchetti D, et al. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 2020;34(1):234–244.
   PubMed Web of Science ®Google Scholar
• Marin-Bejar O, Marchese FP, Athie A, et al. Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. Genome Biol. 2013;14(9):R104.
   PubMed Web of Science ®Google Scholar
• Li N, Richard S. Sam68 functions as a transcriptional coactivator of the p53 tumor suppressor. Nucleic Acids Res. 2016;44(18):8726–8741.
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Panda AC, Kang MJ, et al. 7SL RNA represses p53 translation by competing with HuR. Nucleic Acids Res. 2014;42(15):10099–10111.
   PubMed Web of Science ®Google Scholar
• Li XL, Subramanian M, Jones MF, et al. Long noncoding RNA PURPL suppresses basal p53 levels and promotes tumorigenicity in colorectal cancer. Cell Rep. 2017;20(10):2408–2423.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Garcia JT, Hung T, et al. An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet. 2016;48(11):1370–1376.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Therneau TMaG PM. Modeling survival data: extending the cox model. New York, NY: Springer; 2000.
   Google Scholar
• Kassambara AK, Survminer M: Drawing survival curves using ‘ggplot2’. 2018. https://CRANR-projectorg/package=survminer
   Google Scholar
• Kanehisa M, Sato Y, Kawashima M, et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457–462.
   PubMed Web of Science ®Google Scholar
• The Gene Ontology C. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330–338.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Wickham, H. Ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016.
   Google Scholar
• Liu Y, Yang N, Peng X, et al. One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy. Biomed Pharmacother. 2019;118:109254.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Lin J, Zhang K, et al. Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma. Cancer Cell Int. 2021;21(1):511.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284.
   PubMed Web of Science ®Google Scholar
• Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017;16(10):718–735.
   PubMed Web of Science ®Google Scholar
• Klein ME, Kovatcheva M, Davis LE, et al. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell. 2018;34(1):9–20.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.
   PubMed Web of Science ®Google Scholar
• Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15(7):482–496.
   PubMed Web of Science ®Google Scholar
• Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705.
   PubMed Web of Science ®Google Scholar
• Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):116.
   PubMed Web of Science ®Google Scholar
• Kanehira M, Fujiwara T, Nakajima S, et al. An lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells. 2017;35(3):739–753.
   PubMed Web of Science ®Google Scholar
• Liu C, Jiang S, Xie H, et al. Long non-coding RNA AC245100.4 contributes to prostate cancer migration via regulating PAR2 and activating p38-MAPK pathway. Med Oncol. 2022;39(5):94.
   PubMed Web of Science ®Google Scholar
• Liu C, Lin P, Zhao J, et al. Knockdown of long noncoding RNA AC245100.4 inhibits the tumorigenesis of prostate cancer cells via the STAT3/NR4A3 axis. Epigenomics. 2021;13(20):1591–1605.
   PubMed Web of Science ®Google Scholar
• Xie H, Zhao J, Wan J, et al. Long noncoding RNA AC245100.4 promotes prostate cancer tumorigenesis via the microRna1455p/RBBP5 axis. Oncol Rep. 2021;45(2):619–629.
   PubMedGoogle Scholar
• Cui R, Liu C, Lin P, et al. LncRNA AC245100.4 binds HSP90 to promote the proliferation of prostate cancer. Epigenomics. 2020;12(15):1257–1271.
   PubMed Web of Science ®Google Scholar
• Yu ZL, Zhu ZM. N6-methyladenosine related long non-coding RNAs and immune cell infiltration in the tumor microenvironment of gastric cancer. Biol Proced Online. 2021;23(1):15.
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhang W, Cao W, et al. Development and validation of an autophagy-related long non-coding RNA prognostic signature for cervical squamous cell carcinoma and endocervical adenocarcinoma. Front Oncol. 2022;12:1049773.
   PubMedGoogle Scholar
• Lu M, Li J, Fan X, et al. Novel immune-related ferroptosis signature in esophageal cancer: an informatics exploration of biological processes related to the TMEM161B-AS1/hsa-miR-27a-3p/GCH1 regulatory network. Front Genet. 2022;13:829384.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang W, Wu Z, et al. Over-expression of lncRNA TMEM161B-AS1 promotes the malignant biological behavior of glioma cells and the resistance to temozolomide via up-regulating the expression of multiple ferroptosis-related genes by sponging hsa-miR-27a-3p. Cell Death Discov. 2021;7(1):311.
   PubMed Web of Science ®Google Scholar
• Gu R, Liu M, Lin P, et al. Correlation analysis of poor prognosis and immunotherapy of lncRnas related with m (6)A modification in cervical cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022;53(4):626–636.
   PubMedGoogle Scholar
• Feng Q, Wang J, Cui N, et al. Autophagy-related long non-coding RNA signature for potential prognostic biomarkers of patients with cervical cancer: a study based on public databases. Ann Transl Med. 2021;9(22):1668.
   PubMed Web of Science ®Google Scholar
• Guan Q, Pan J, Ren N, et al. Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma. Front Cell Dev Biol. 2022;10:960277.
   PubMed Web of Science ®Google Scholar
• Rishehri M, Etemadi T, Pisheh L, et al. Quantitative expression of SFN, lncRNA CCDC18-AS1, and lncRNA LINC01343 in human breast cancer as the regulator biomarkers in a novel ceRNA network: based on bioinformatics and experimental analyses. Genet Res (Camb). 2022;2022:6787791.
   PubMed Web of Science ®Google Scholar
• Zhou S, Fang J, Sun Y, et al. Integrated analysis of a risk score system predicting prognosis and a ceRNA network for differentially expressed lncrnas in multiple myeloma. Front Genet. 2020;11:934.
   PubMed Web of Science ®Google Scholar
• Yan T, Ma G, Wang K, et al. The immune heterogeneity between pulmonary adenocarcinoma and squamous cell carcinoma: a comprehensive analysis based on lncRNA model. Front Immunol. 2021;12:547333.
   PubMed Web of Science ®Google Scholar
• Cai Z, Tang B, Chen L, et al. Mast cell marker gene signature in head and neck squamous cell carcinoma. BMC Cancer. 2022;22(1):577.
   PubMedGoogle Scholar
• Luan L, Dai Y, Shen T, et al. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Front Immunol. 2022;13:951455.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–686.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945.
   PubMed Web of Science ®Google Scholar
• Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813–827.
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349–352.
   PubMed Web of Science ®Google Scholar
• Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729–740.
   PubMed Web of Science ®Google Scholar
• Fujita K, Mondal AM, Horikawa I, et al. P53 isoforms delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11(9):1135–1142.
   PubMed Web of Science ®Google Scholar
• d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426(6963):194–198.
   PubMed Web of Science ®Google Scholar
• Cazzalini O, Scovassi AI, Savio M, et al. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res. 2010;704(1–3):12–20.
   PubMed Web of Science ®Google Scholar
• Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. Embo J. 2003;22(16):4212–4222.
   PubMed Web of Science ®Google Scholar
• Jacobs JJ, de Lange T. Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol. 2004;14(24):2302–2308.
   PubMed Web of Science ®Google Scholar